Overview

A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (

Status:
Completed

Trial end date:
2018-01-31

Target enrollment:

Participant gender:

Summary

The purpose of this study was to assess whether the progression free survival (PFS) time with FOLFOX-4 plus cetuximab is longer than that with FOLFOX-4 alone as first-line treatment for mCRC in Chinese subjects with RAS wild-type tumors.

Phase:

Phase 3

Details

Lead Sponsor:

Merck KGaA
Merck KGaA, Darmstadt, Germany

Treatments:

Cetuximab
Fluorouracil
Folic Acid
Leucovorin
Levoleucovorin
Oxaliplatin